Skip to main content

Major Depressive Disorder

Although long suspected of causing depression and other psychiatric symptoms in patients undergoing treatment for cardiovascular disease, beta-blockers are not associated with increased risk of depression, according to a systematic review and meta-analysis.
More than half of 3904 US adults with previous COVID-19 illness met criteria for moderate or greater symptoms of major depressive disorder months later, according to a study published online in a research letter in JAMA Network Open.
Sage Therapeutics has released complete data from a 12-month study of patients taking 30 mg of zuranolone for major depressive disorder and interim data on a cohort receiving a 50 mg dose.
Nearly half of people who had recovered from acute COVID-19 reported moderate to severe depressive symptoms, researchers found in a study published in the International Journal of Environmental Research and Public Health.
The widely held assumption that individual differences underlie the variability in the association between total depression scores and antidepressant treatment may not be valid, according to a meta-analysis recently published online in JAMA Psychiatry.
Bernhard T. Baune, PhD, MD, head of the Department of Mental Health at the University of Münster, Germany, discusses the research needed to improve clinicians' understanding of cognition in patients…
Psych Congress Steering Committee member Charles Raison, MD, recently joined the Ottawa Institute of Cognitive Behavioural Therapy for an examination of depression through an evolutionary lens.
Two members of the Psych Congress Steering Committee have been featured on an ABC News podcast which grew out of a newsman's newfound interest in meditation.
Listen as Psych Congress Steering Committee member Charles Raison, MD, discusses a book he coauthored, The New Mind-Body Science of Depression, with David Van Nuys, PhD, on Shrink Rap Radio.
Back to Top